"Lipopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds consisting of a short peptide chain conjugated with an acyl chain.
| Descriptor ID |
D055666
|
| MeSH Number(s) |
D10.477 D12.644.365
|
| Concept/Terms |
Anionic Lipopeptides- Anionic Lipopeptides
- Lipopeptides, Anionic
- Anionic Lipopeptide
- Lipopeptide, Anionic
Cationic Lipopeptides- Cationic Lipopeptides
- Lipopeptides, Cationic
- Cationic Lipopeptide
- Lipopeptide, Cationic
|
Below are MeSH descriptors whose meaning is more general than "Lipopeptides".
Below are MeSH descriptors whose meaning is more specific than "Lipopeptides".
This graph shows the total number of publications written about "Lipopeptides" by people in this website by year, and whether "Lipopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipopeptides" by people in Profiles.
-
Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species. Pharmacotherapy. 2023 06; 43(6):466-472.
-
Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
-
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
-
Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
-
Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
-
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.